
US-based precision medicine firm offering LDTs for disease prediction, molecular pathways, and drug options.
Founded in Charlottesville, United States, Ampel Biosolutions is a precision medicine company dedicated to revolutionizing the management of autoimmune and inflammatory diseases. Their core mission is to provide personalized, predictive care through advanced RNA analytics and AI-driven insights. Ampel offers Laboratory Developed Tests (LDTs) that predict disease status, identify molecular pathways, and suggest optimal drug options. Their market focus includes conditions such as lupus, dermatology issues, nephrology, fibromyalgia, cardiology, arthritis, and infections.
Notable figures affiliated with Ampel Biosolutions include a distinguished executive team and advisory group comprising experts in precision medicine and AI. The company has made significant strides in the healthcare sector by publishing influential research papers and forming strategic partnerships. Ampel's innovative approach has garnered attention for its potential to transform patient care and improve outcomes through tailored treatment strategies.

Amplified Sciences

BioAmp diagnostics
bioampdx.com

Ariel Precision Medicine
arielmedicine.com

Amprion

Ampersand Biomedicines
ampersand.bio

HI-Bio
hibio.com

Amplifica
amplificabio.com

Ampere Life Sciences

bioSyntagma
biosyntagma.com

Path BioAnalytics

AMPLY Discovery
amplydiscovery.com

Santa Ana Bio
santaanabio.com

Aperture Bio
aperture.bio

Amplo Biotechnology

Amydis
amydis.com
Companies similar to Ampel Biosolutions include Amplified Sciences, BioAmp diagnostics, Ariel Precision Medicine and Amprion.
Ampel Biosolutions was founded in 2013.
Ampel Biosolutions' headquarters is located in Charlottesville, VA, US.
Ampel Biosolutions' most recent funding round was for $1.8M (USD) in July 2023.
As of Jul 6, 2023, Ampel Biosolutions has raised a total of $14.3M (USD).
Ampel Biosolutions has 29 employees as of Feb 4, 2024.